Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
19.31
-0.32 (-1.63%)
At close: Oct 17, 2025, 4:00 PM EDT
19.33
+0.02 (0.10%)
After-hours: Oct 17, 2025, 7:54 PM EDT
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 36,830 employees as of December 31, 2024. The number of employees decreased by 1,021 or -2.70% compared to the previous year.
Employees
36,830
Change (1Y)
-1,021
Growth (1Y)
-2.70%
Revenue / Employee
$451,480
Profits / Employee
-$4,263
Market Cap
22.15B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TEVA News
- 2 days ago - Teva Vs. Viatris: Who Will Dominate In President Trump's America? - Seeking Alpha
- 9 days ago - FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - GlobeNewsWire
- 12 days ago - Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside - Seeking Alpha
- 24 days ago - Teva Releases Q3 2025 Aide Memoire - GlobeNewsWire
- 24 days ago - Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 - GlobeNewsWire
- 24 days ago - Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors - Seeking Alpha
- 25 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 27 days ago - Teva Pharmaceutical Industries Limited - Special Call - Seeking Alpha